First line chemotherapy of metastatic breast cancer
- 1 May 2006
- journal article
- research article
- Published by Elsevier in Annals of Oncology
- Vol. 17 (suppl_5) , v165-v168
- https://doi.org/10.1093/annonc/mdj974
Abstract
In the last 20–30 years the approach to metastatic breast cancer by chemotherapy has been largely studied. Anthracyclines, taxanes and, more recently, capecitabine and gemcitabine represent the breakthrough of treatment. In the next future the combination of chemotherapy and target therapy will be considered more frequently.Keywords
This publication has 36 references indexed in Scilit:
- Taxane containing regimens for metastatic breast cancerPublished by Wiley ,2003
- Superior Survival With Capecitabine Plus Docetaxel Combination Therapy in Anthracycline-Pretreated Patients With Advanced Breast Cancer: Phase III Trial ResultsJournal of Clinical Oncology, 2002
- Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2New England Journal of Medicine, 2001
- Prospective Randomized Trial of Docetaxel Versus Mitomycin Plus Vinblastine in Patients With Metastatic Breast Cancer Progressing Despite Previous Anthracycline-Containing ChemotherapyJournal of Clinical Oncology, 1999
- Results and long term follow-up for 1581 patients with metastatic breast carcinoma treated with standard dose doxorubicin-containing chemotherapyCancer, 1999
- Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women.Journal of Clinical Oncology, 1998
- Treatment of Breast CancerNew England Journal of Medicine, 1998
- Docetaxel.Journal of Clinical Oncology, 1995
- Chemotherapy and survival in advanced breast cancer: the inclusion of doxorubicin in Cooper type regimensBritish Journal of Cancer, 1993
- Phase II Trial of Taxol, an Active Drug in the Treatment of Metastatic Breast CancerJNCI Journal of the National Cancer Institute, 1991